新世紀醫療控股有限公司
New Century Healthcare Holding Co. Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1518)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

2026 INTERIM RESULTS HIGHLIGHTS

Set forth below are our key performance highlights for the six months ended June 30, 2026:

1. Our revenue amounted to RMB249.0 million for the six months ended June 30, 2026, which was a decrease compared to our revenue recorded in the same period last year.

2. We recorded a loss before income tax of RMB95.5 million for the six months ended June 30, 2026, which was primarily due to (i) the decrease in the number of inpatient visits and outpatient visits in the first half of 2026; (ii) the increase in other losses, net resulting from the provision of approximately RMB62.1 million for the expected payment amount in connection with the freeze of certain bank accounts of the Group mainly relating to an investigation by the Supervisory Committee.

KEY OPERATIONAL DATA

	For the six months ended June 30,		
	2026	2025	Change
Revenue from medical services attributable to outpatients *(RMB'000)*	**152,342**	182,520	(16.5)%
Outpatient visits	**83,862**	103,344	(18.9)%
Revenue from medical services attributable to inpatients *(RMB'000)*	**80,967**	102,786	(21.2)%
Inpatient visits	**2,785**	3,411	(18.4)%

Our Board is pleased to announce the interim unaudited condensed consolidated financial results of our Group for the six months ended June 30, 2026 together with the comparative figures as set out below.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

		Six months ended June 30,	
		2026	**2025**
	Notes	***RMB'000***	*RMB'000*
		(Unaudited)	**(Unaudited)**
Revenue	*3*	**248,958**	304,528
Cost of revenue	*3*	**(187,776)**	(214,882)
Impairment losses on non-current assets		**—**	(33,737)
Selling expenses		**(27,706)**	(33,921)
Administrative expenses		**(54,982)**	(59,053)
Research and development expenses		**(855)**	(1,809)
Net impairment losses on financial assets		**(9,223)**	(1,570)
Other income		**484**	525
Other losses — net	*4*	**(61,536)**	(176)
Operating loss		**(92,636)**	(40,095)
Finance income		**549**	1,666
Finance costs		**(4,023)**	(3,570)
Share of net profits of investments accounted for using the equity method		**566**	911
Loss before income tax		**(95,544)**	(41,088)
Income tax expense	*5*	**(5,895)**	(17,719)
Loss for the interim period		**(101,439)**	(58,807)
Loss for the interim period attributable to:			
Owners of the Company		**(84,959)**	(65,234)
Non-controlling interests		**(16,480)**	6,427

	Notes	Six months ended June 30, 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Other comprehensive income			
Items that may be reclassified to profit or loss			
— Exchange differences on translation of foreign operations		**(35)**	73
Total comprehensive income for the interim period		**(101,474)**	(58,734)
Total comprehensive income for the interim period attributable to:			
Owners of the Company		**(84,994)**	(65,161)
Non-controlling interests		**(16,480)**	6,427
Loss per share for loss attributable to the ordinary equity holders of the Company *(expressed in RMB per share)*			
Basic and diluted loss per share	*6*	**(0.18)**	(0.14)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Notes	**As of June 30, 2026** *RMB'000* **(Unaudited)**	As of December 31, 2025 *RMB'000* (Audited)
ASSETS			
Non-current assets			
Property, plant and equipment		**53,977**	59,746
Right-of-use assets		**87,934**	100,333
Intangible assets		**205,775**	208,755
Investments accounted for using the equity method		**15,866**	15,335
Deferred tax assets		**148**	779
Long-term deposits and prepayments		**3,518**	3,514
Total non-current assets		**367,218**	388,462
Current assets			
Inventories		**10,218**	12,761
Trade receivables	*7*	**23,244**	31,038
Other receivables, deposits and prepayments		**16,253**	16,548
Amounts due from related parties		**4,933**	13,052
Term deposits		**—**	53,200
Restricted cash	*8*	**217,497**	—
Cash and cash equivalents		**61,527**	230,260
Total current assets		**333,672**	356,859
Total assets		**700,890**	745,321
EQUITY			
Share capital		**335**	335
Shares held for employee share scheme		**(2,939)**	(2,939)
Share premium		**2,580,078**	2,580,078
Reserves		**(1,485,382)**	(1,485,347)
Accumulated losses		**(748,298)**	(663,339)
Equity attributable to owners of the Company		**343,794**	428,788
Non-controlling interests		**(91,294)**	(74,814)
Total equity		**252,500**	353,974

	Notes	As of June 30, 2026 RMB'000 (Unaudited)	As of December 31, 2025 RMB'000 (Audited)
LIABILITIES			
Non-current liabilities			
Lease liabilities		**76,862**	95,940
Deferred tax liabilities		**17,161**	17,756
Total non-current liabilities		**94,023**	113,696
Current liabilities			
Trade payables	*9*	**22,435**	24,575
Accruals, other payables and provisions	*10*	**202,261**	143,918
Lease liabilities		**87,218**	70,300
Contract liabilities		**37,470**	35,378
Current tax liabilities		**484**	683
Amounts due to related parties		**4,499**	2,797
Total current liabilities		**354,367**	277,651
Total liabilities		**448,390**	391,347
Total equity and liabilities		**700,890**	745,321

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1 GENERAL INFORMATION

New Century Healthcare Holding Co. Limited (the "**Company**") and its subsidiaries (together, the "**Group**") are principally engaged in provision of pediatrics, obstetrics and gynecology specialty services in the People's Republic of China (the "**PRC**"). The Group also provides online healthcare services and other related services.

The Company is a limited liability company incorporated in the Cayman Islands on July 31, 2015. The address of its registered office is c/o Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.

The ordinary shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited ("**the Listing**") on January 18, 2017.

The interim condensed consolidated financial information is presented in Renminbi ("**RMB**") and rounded to nearest thousand yuan, unless otherwise stated.

2 BASIS OF PREPARATION OF THE INTERIM REPORT

This interim condensed consolidated financial information for the six-month period ended June 30, 2026 has been prepared in accordance with Hong Kong Accounting Standard 34 ("**HKAS 34**") 'Interim financial reporting'.

Going Concern

For the six months ended June 30, 2026, the Group had net operating loss of RMB92,636,000 and net loss attributable to owners of the Company of RMB84,959,000. As at June 30, 2026, the Group's current liabilities exceeded its current assets by RMB20,695,000.

As disclosed in Note 8 and Note 10(i), certain bank accounts of the Group, amounting to approximately RMB217,497,000, were frozen and the Group has recognised a provision of approximately RMB62,125,000 for a probable payment to resolve the matter. These events and circumstances may cast significant doubts on the Group's ability to continue as a going concern.

In view of the above circumstances, management have prepared cash flow forecasts covering a period of not less than twelve months from the date of this interim condensed consolidated financial information given careful consideration to the Group's future liquidity, performance and available sources of financing. In making these forecasts, management have considered the Group's active engagement with the relevant Supervisory Committee to facilitate the resolution of the Freeze Action and the release of the restriction on the frozen funds. These forecasts take into account the Group's operating cash flows, as well as the anticipated release of the restrictions on the frozen funds, the expected payment described above, and also considered the potential timing of these events. Based on this forecast, the Directors consider that the Group will have sufficient cash resources to meet its obligations as and when they fall due throughout the forecast period. Accordingly, the directors are of the opinion that it remains appropriate to prepare the interim condensed consolidated financial information on a going concern basis.

The interim condensed consolidated financial information does not include all of the notes normally included in annual consolidated financial statements. Accordingly, this interim condensed consolidated financial information should be read in conjunction with the annual consolidated financial statements for the year ended December 31, 2025.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except for the adoption of new and amended standards as below.

(a) New and amended standards adopted by the Group

A number of new or amended standards became applicable during current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting these standards.

(b) Impact of standards issued but not yet adopted by the Group

Certain new accounting standards, amendments to existing accounting standards and interpretations have been published that are not mandatory for the current reporting period and have not been early adopted by the Group. Except for the expected changes in presentation and disclosure under HKFRS 18 as mentioned in the annual financial report for the year ended December 31, 2025, other standards are not expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions.

3 SEGMENT INFORMATION

Mr. Jason ZHOU, in his role as the executive director and chairman of the Company, serves as the chief operating decision-maker (the "**CODM**") of the Group. Management has determined the operating segments based on the information reviewed by the CODM for the purposes of allocating resources and assessing performance.

In the view of the CODM, the Group is principally engaged in three distinct segments which are subject to different business risks and economic characteristics: (i) pediatric services, (ii) obstetrics and gynecology services, and (iii) others, including hospital appointment, online consultation services and online products sales to customers, canteens operation, sales of gift and groceries in shops located in its own hospitals. Management group these revenue in others as each of them does not exceed 10% of the total revenue, total profit and total assets of the Group.

The Group's segment information is shown as follows:

(i) Segment information

	Pediatrics *RMB'000*	Obstetrics and gynecology *RMB'000*	Others *RMB'000*	Intersegment eliminations *RMB'000*	Unallocated *RMB'000*	Total *RMB'000*
(Unaudited)						
Six months ended June 30, 2026						
Revenue from external customers	204,581	40,924	3,453	—	—	248,958
Inter-segment revenue	—	—	8,080	(8,080)	—	—
Total revenue	204,581	40,924	11,533	(8,080)	—	248,958
Cost of revenue	(144,351)	(39,015)	(6,867)	2,457	—	(187,776)
Segment results	2,854	(11,501)	(5,335)	—	—	(13,982)
Unallocated income					2,358	2,358
Unallocated cost					(83,920)	(83,920)
Profit/(loss) before income tax	2,854	(11,501)	(5,335)	—	(81,562)	(95,544)
Income tax expense					(5,895)	(5,895)
Loss for the period						(101,439)
Others						
Depreciation and amortisation	15,581	5,429	409	—	243	21,662
As of June 30, 2026						
Total assets	341,425	52,716	8,622	—	298,127	700,890
Total liabilities	218,686	115,339	6,423	—	107,942	448,390

	Pediatrics *RMB'000*	Obstetrics and gynecology *RMB'000*	Others *RMB'000*	Intersegment eliminations *RMB'000*	Unallocated *RMB'000*	Total *RMB'000*
(Unaudited)						
Six months ended June 30, 2025						
Revenue from external customers	255,693	45,312	3,523	—	—	304,528
Inter-segment revenue	—	—	14,688	(14,688)	—	—
Total revenue	255,693	45,312	18,211	(14,688)	—	304,528
Cost of revenue	(164,642)	(45,214)	(8,055)	3,029	—	(214,882)
Impairment losses on non-current assets	(20,571)	(13,166)	—	—	—	(33,737)
Segment results	(507)	(28,636)	2,883	—	—	(26,260)
Unallocated income					3,160	3,160
Unallocated cost					(17,988)	(17,988)
(Loss)/profit before income tax	(507)	(28,636)	2,883	—	(14,828)	(41,088)
Income tax expense					(17,719)	(17,719)
Loss for the period						(58,807)
Others						
Depreciation and amortisation	17,949	6,247	409	—	427	25,032
As of December 31, 2025						
Total assets	368,070	56,178	17,316	—	303,757	745,321
Total liabilities	225,526	112,548	7,356	—	45,917	391,347

(ii) Disaggregation of revenue from contracts with customers

Substantially all of the Group's revenue from external customers is recognised at a point in time.

(iii) No geographical information is presented as all of the Group's revenue is derived from activities in the PRC, and the Group's operations and non-current assets are mainly located in the PRC.

4 OTHER LOSSES — NET

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Provision *(Note 10)*	**62,125**	—
Others	**(589)**	176
	61,536	176

5 INCOME TAX EXPENSE

	Six months ended June 30, 2026 *RMB'000* (Unaudited)	2025 *RMB'000* (Unaudited)
Current income tax:		
— PRC corporate income tax	**5,859**	9,200
Deferred income tax	**36**	8,519
	5,895	17,719

(a) Cayman Islands income tax

The Company is incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Act of Cayman Islands and accordingly, is exempted from Cayman Islands income tax.

(b) PRC Corporate Income Tax

Subsidiaries established and operating in Mainland China are subject to PRC corporate income tax at the rate of 25%.

(c) Hong Kong profits tax

Hong Kong profits tax rate is 16.5% for the six months ended June 30, 2026 and 2025. No Hong Kong profit tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax for the six months ended June 30, 2026 and 2025.

6 LOSS PER SHARE

(a) Basic

Basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of ordinary shares in issue and excluding shares held for restricted share award scheme.

	Six months ended June 30, 2026 (Unaudited)	2025 (Unaudited)
Loss attributable to owners of the Company *(RMB'000)*	**(84,959)**	(65,234)
Weighted average number of ordinary shares in issue *(in thousands)* (i)	**483,184**	483,184
Basic loss per share *(in RMB)*	**(0.18)**	(0.14)

(i) On July 25, 2017, the Company granted 9,000,000 restricted shares to certain employees pursuant to a restricted share award scheme, among which 4,767,500 shares were forfeited and then held by the trustee of the restricted share award scheme. Those forfeited shares were excluded from the calculation of basic loss per share.

As at June 30, 2026, the Company held 2,073,500 (2025: 2,073,500) shares of the Company for employee share scheme. All these shares were excluded from calculation of basic loss per share as no shares were granted to employees and outstanding as at June 30, 2026.

(b) Diluted

For the six months ended June 30, 2026 and 2025, diluted loss per share is equal to the basic loss per share as there were no potential dilutive shares.

7 TRADE RECEIVABLES

	As of June 30, 2026	As of December 31, 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables from contracts with customers	**24,076**	31,996
Less: allowance for impairment of trade receivables	**(832)**	(958)
Trade receivables — net	**23,244**	31,038

The carrying amounts of the Group's trade receivables are denominated in RMB and approximate their fair values. The majority of trade receivables were due from commercial insurance companies and government's insurance schemes.

As at June 30, 2026 and December 31, 2025, the aging analysis of the trade receivables based on demand note date was as follows:

	As of June 30, 2026	As of December 31, 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Up to 3 months	**20,174**	26,588
4–6 months	**1,747**	2,184
7 months–1 year	**785**	1,606
Over 1 year	**1,370**	1,618
	24,076	31,996

8 RESTRICTED CASH

	As of June 30, 2026 *RMB'000* (Unaudited)	As of December 31, 2025 *RMB'000* (Audited)
Restricted cash	**217,497**	—

As disclosed in Note 10(i), RMB217,497,000 of the Group's bank accounts as at June 30, 2026 were frozen. Management expects the restrictions on the frozen funds to be released within the next twelve months based on current circumstances, and accordingly, the restricted cash have been classified as current assets in the condensed consolidated financial information.

9 TRADE PAYABLES

As at June 30, 2026 and December 31, 2025, the aging analysis of the trade payables based on demand note date was as follows:

	As of June 30, 2026 *RMB'000* (Unaudited)	As of December 31, 2025 *RMB'000* (Audited)
Up to 3 months	**13,042**	20,573
4–6 months	**5,486**	2,611
7 months–1 year	**2,739**	372
Over 1 year	**1,168**	1,019
	22,435	24,575

10 ACCRUALS, OTHER PAYABLES AND PROVISIONS

	As of June 30, 2026 *RMB'000* **(Unaudited)**	As of December 31, 2025 *RMB'000* (Audited)
Advance from customers	**65,228**	72,420
Provision (i)	**62,125**	—
Accrued employee benefits	**27,797**	28,998
Accrued operating expenses	**24,538**	20,273
Other payables to suppliers of plant and equipment	**8,927**	9,565
Duty and tax payable other than corporate income tax	**1,997**	2,239
Others	**11,649**	10,423
	202,261	143,918

(i) As disclosed in the Company's announcement dated August 14, 2026, certain bank accounts of the Group, amounting to approximately RMB217,497,000, were frozen primarily in connection with an ongoing investigation (the "**Investigation**") by the Beijing Mentougou Supervisory Committee (北京市門頭溝區監察委員會) (the "**Supervisory Committee**") involving one of the Company's cooperative partners (the "**Freeze Action**"). The Investigation is not initiated against the Group, its directors or its senior management. Based on the Group's assessment and advice from external legal counsel, the Group has not identified any breach of the public-private-partnership arrangement between the Group and the cooperative partners. However, according to the communication between the Supervisory Committee and the Company, there exist different views on certain matters relating to the Group's public-private-partnership arrangement, which involves the use of premises owned by the cooperative partner. Based on the Group's latest communications with the Supervisory Committee, the Group has recognised a provision of approximately RMB62,125,000 for probable payment to resolve the matter. Such amount represents management's best estimate of the payment amount which was calculated based on certain premises related costs incurred by the cooperative partner plus the financing cost of such expenditure, and the latest communications with the Supervisory Committee. As of the date of approval of this interim condensed consolidated financial information, the Investigation remains ongoing, and uncertainty remains regarding the outcome of the Investigation and the resolution of the matter, including the final payment amount and the timing and extent of the release of the frozen funds. Consequently, the aforementioned provision recognised may be subject to further adjustment upon completion of the Investigation.

11 DIVIDENDS

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Dividends paid during the interim period of HKD0.0221 per fully paid ordinary share (i)	**—**	7,996

(i) Pursuant to the shareholders resolution of the Company dated May 22, 2025, a final dividend amounting to HKD10,830,000 (approximate RMB9,948,000) of HKD0.0221 per fully paid ordinary share was declared. The dividends attributable to shares held by the trustee of the restricted share award scheme and shares held for employee share scheme were eliminated in the condensed consolidated statement of financial position of the Group, dividends of HKD10,678,000 (approximate RMB9,809,000) after elimination were recorded in the condensed consolidated statement of changes in equity of the Group, accordingly. For the six months ended June 30, 2025, HKD8,705,000 (approximate RMB7,996,000) of the final dividend was paid by the Company. The remaining dividend was recognised in accruals, other payables and provisions in the interim condensed consolidated financial information.

(ii) The board of directors of the Company does not resolve to declare an interim dividend for the six months ended June 30, 2026.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Overview and Outlook

Our Group's business recorded a revenue of RMB249.0 million, representing a 18.2% YoY decrease when compared to the same period in last year. Our revenue from medical services was RMB245.5 million, representing a 18.4% YoY decrease, among which, the revenue from pediatric services recorded a 20.0% YoY decrease to RMB204.6 million, accounting for 83.3% of the total revenue from medical services. Our revenue from pediatric outpatient services recorded a 19.7% YoY decrease to RMB128.0 million. The number of pediatric services outpatient visits was 70,699, representing a 19.7% YoY decrease. Our revenue from pediatric inpatient services recorded a 20.1% YoY decrease to RMB64.3 million. The number of pediatric services inpatient visits was 2,197, representing a 17.1% YoY decrease.

In the first half of 2026, our revenue from obstetric and gynecologic business recorded a 9.7% YoY decrease to RMB40.9 million. Our revenue from obstetric and gynecologic outpatient services recorded a 5.7% YoY increase to RMB24.3 million; the number of obstetric and gynecologic services outpatient visits was 13,163, representing a 14.0% YoY decrease. Our revenue from obstetric and gynecologic inpatient services was RMB16.6 million, representing a 25.6% YoY decrease. The number of obstetric and gynecologic services inpatient visits reached 588, representing a 22.6% YoY decrease.

Being a leading private pediatrics, and obstetrics and gynecologic healthcare service provider in Beijing as well as in China, we provide integrated medical services to customers in respect of pediatrics, and obstetrics and gynecology, and we are characterized by providing comprehensive and in-depth pediatric medical services. Revenue for the first half of 2026 decreased significantly compared to the same period in 2025, primarily due to a decline in demand for pediatric and obstetric and gynecologic medical services. The overall reduction in newborn population in recent years has led to a decrease year by year in the infant population served by the Group. Additionally, the incidence of infectious diseases in internal medicine in 2026 has markedly declined compared to the last year, resulting in significant reductions in both outpatient and inpatient visits for pediatric internal medicine, with corresponding substantial decreases in revenue. The reduced demand for pediatric infectious disease treatment has further diminished customer willingness to renew membership and purchase commercial insurance. In response to this situation, the Group has implemented tiered membership cards and long-term loyalty programs across multiple hospitals.

The loss attributable to the owners of our Company amounted to RMB85.0 million for the six months ended June 30, 2026, mainly attributable to the decline in demand for medical business in the first half of 2026 and the significant increase in other losses resulting from the provision made for the expected payment amount in connection with the freeze of certain bank accounts of the Group mainly relating to an investigation by the Supervisory Committee.

Industry Outlook and our Group's Strategies

The comprehensive development of healthcare services in respect of women and children has been highly emphasized by the PRC. In September 2021, the State Council issued the "Outline on the Development of Chinese Women (2021–2030)" and "Outline on the Development of Chinese Children (2021–2030)", which are of great significance in promoting the high-quality development of China's women and children's healthcare business. The "Notice of the National Health Commission on Publishing the Implementation Plan for the 2021–2030 Outlines for the Development of Chinese Women and Children" issued in April 2022 provides further guidance. China's women and children's health work still faces many challenges such as insufficient total service resources, uneven distribution, and a shortage of high-quality resources. Especially since the adjustment of the birth policy, the proportion of advanced age and multiparous women has increased, the risk of complications, comorbidities, and birth defects during pregnancy have increased, and the demand for newborn safety and child healthcare services has further increased, triggering (i) a significant increase in the market demand for the provision of whole-cycle, whole-process and all-round medical and healthcare services to women and children; and (ii) more stringent requirements regarding medical service capabilities, service modes and service principle.

In order to further promote the refined management of medical insurance and boost the utilization efficiency of medical insurance funds, the National Healthcare Security Administration published a notice on November 26, 2021 regarding the "Three-Year Action Plan for DRG/DIP Payment Reform", in which it is stated that DRG/DIP Payment will be carried out in all planning areas in the PRC by the end of 2024 and DRG/DIP Payment will cover all qualified medical institutions providing inpatient services by the end of 2025, basically achieving a full coverage on diseases and medical insurance funds. The full implementation of DRG/DIP Payment in designated medical institutions will raise the requirements on the medical technology level of private high-end medical institutions, which further highlights their advantages and attracts people with long-term illness, complicated illness and mid-end to high-end commercial medical insurance to pursue quality medical services.

Adhering to the previously formulated development strategies, our Group intends to grasp the industry opportunities by implementing the following measures in the second half of 2026:

- In response to changes in payment policies of the domestic basic medical insurance, the Group continues to strengthen the Group's brand promotion among mid-end to high-end commercial insurance institutions to expand coverage of target customer base.

- We will implement a tiered membership card strategy, lowering renewal thresholds for long-term members to maintain renewal rates and stabilize both the member base calculated by household units and service penetration rates.

- We will focus on developing pediatric subspecialty services and restructure our child healthcare product offerings.
- We will streamline workforce composition to enhance workforce productivity.

FINANCIAL REVIEW

Segment Revenue

We generate revenue primarily from providing medical services, including pediatric services, and obstetric and gynecologic services. The following table sets forth a breakdown of the revenue for the periods indicated:

	Six months ended June 30,			
	2026		2025	
	(in thousands of RMB, except percentages)			
Medical services	**245,505**	**98.6%**	301,005	98.8%
Others[1]	**3,453**	**1.4%**	3,523	1.2%
Total	**248,958**	**100.0%**	304,528	100.0%

(1) Others mainly include revenue from cafeteria and gift shop sales at our medical institutions and online healthcare services after intersegment elimination.

Medical Services

Our revenue from the provision of medical services consists of healthcare services fees and revenue from pharmaceutical sales. The following table sets forth the revenue, cost of revenue, gross profit and gross profit margin of our medical services for the periods indicated:

	Six months ended June 30,	
	2026	2025
	(in thousands of RMB, except percentages)	
Revenue	**245,505**	301,005
Cost of revenue	**183,366**	209,856
Gross profit[1]	**62,139**	91,149
Gross profit margin[2]	**25.3%**	30.3%

Notes:

(1) Gross profit is calculated by deducting cost of revenue from revenue.

(2) Gross profit margin is calculated by dividing gross profit by revenue and multiplied by 100%.

The following table sets forth the composition of our revenue from pediatric, and obstetric and gynecologic services for the periods indicated:

	Six months ended June 30,			
	2026		2025	
	(in thousands of RMB, except percentages)			
Pediatric services	**204,581**	**82.2%**	255,693	84.0%
Obstetric and gynecologic services	**40,924**	**16.4%**	45,312	14.8%
Total	**245,505**	**98.6%**	301,005	98.8%

Our medical services can also be classified by service and sale to inpatients and outpatients and membership card sales. The following table sets forth revenue and certain data relating to such classification for the periods indicated:

	Six months ended June 30,	
	2026	2025
Our Group		
Inpatients services		
Inpatient visits	**2,785**	3,411
Average inpatient spending per visit *(RMB)*	**29,073**	30,134
Outpatients services		
Outpatient visits	**83,862**	103,344
Average outpatient spending per visit *(RMB)*	**1,817**	1,766
Revenue from medical services attributable to inpatients *(RMB'000)*	**80,967**	102,786
Revenue from medical services attributable to outpatients *(RMB'000)*	**152,342**	182,520
Revenue recognized for membership card sales *(RMB'000)*	**12,196**	15,699
Pediatric Services		
Inpatient services		
Inpatient visits	**2,197**	2,651
Average inpatient spending per visit *(RMB)*	**29,285**	30,368
Outpatient services		
Outpatient visits	**70,699**	88,045
Average outpatient spending per visit *(RMB)*	**1,811**	1,811

	Six months ended June 30,	
	2026	2025
Revenue from pediatric services attributable to inpatients *(RMB'000)*	**64,339**	80,505
Revenue from pediatric services attributable to outpatients *(RMB'000)*	**128,046**	159,489
Revenue recognized for membership card sales *(RMB'000)*	**12,196**	15,699
Obstetric and gynecologic services		
Inpatient services		
Inpatient visits	**588**	760
Average inpatient spending per visit *(RMB)*	**28,279**	29,317
Outpatient services		
Outpatient visits	**13,163**	15,299
Average outpatient spending per visit *(RMB)*	**1,846**	1,505
Revenue from obstetric and gynecologic services attributable to inpatients *(RMB'000)*	**16,628**	22,281
Revenue from obstetric and gynecologic services attributable to outpatients *(RMB'000)*	**24,296**	23,031

The revenue generated from the provision of our medical services amounted to RMB245.5 million for the six months ended June 30, 2026, representing a 18.4% YoY decrease and accounting for 98.6% of our Group's total revenue. Such decrease was primarily due to (i) a 16.5% decrease and 21.2% decrease in revenue from medical services attributable to the outpatients and inpatients respectively; and (ii) a 22.3% YoY decrease in revenue recognized for membership card sales.

In particular, our medical services were composed of pediatric services, and obstetric and gynecologic services, from which we generated a revenue of RMB204.6 million and RMB40.9 million, respectively, for the six months ended June 30, 2026, representing a YoY decrease of 20.0% and a YoY decrease of 9.7%, respectively, when compared with the same period in the previous financial year. For the six months ended June 30, 2026, we recorded (i) a total of 2,197 inpatient visits and 70,699 outpatient visits for our pediatric services, representing a YoY decrease of 17.1% and a YoY decrease of 19.7%, respectively; and (ii) a total of 588 inpatient visits and 13,163 outpatient visits for our obstetric and gynecologic services, representing a YoY decrease of 22.6% and a YoY decrease of 14.0%, respectively.

The cost of revenue of our medical services consists primarily of employee benefits expenses, cost of inventories and consumables, consultation fees, depreciation and amortisation, outsourced examination and inspection fees and utilities, maintenance fees and office expenses. The cost of revenue of our medical services for the six months ended June 30, 2026 reached RMB183.4 million, representing a YoY decrease of 12.6%.

Gross Profit and Gross Profit Margin

Our gross profit for the six months ended June 30, 2026 amounted to RMB61.2 million, representing a YoY decrease of 31.7% when compared with our gross profit of RMB89.6 million for the same period in the previous financial year. This was mainly due to the lower demand for pediatric, and obstetric and gynecologic medicine services. Our gross profit margin decreased from 29.4% in the six months ended June 30, 2025 to 24.6% in the six months ended June 30, 2026.

Selling Expenses

Our selling expenses for the six months ended June 30, 2026 amounted to RMB27.7 million, representing a YoY decrease of 18.3% when compared with our selling expenses of RMB33.9 million for the same period in the previous financial year. This reduction was primarily due to the decrease in employee benefits expenses.

Administrative Expenses

Our administrative expenses for the six months ended June 30, 2026 amounted to RMB55.0 million, representing a YoY decrease of 6.9% when compared with our administrative expenses of RMB59.1 million for the same period in the previous financial year. Such decrease was mainly a result of the measures continuously carried out by us to reduce expenses and improve operational efficiency in 2026.

Impairment Losses on Financial Assets

During the six months ended June 30, 2026, our Group recorded net impairment losses on financial assets amounting to RMB9.2 million, which was mainly due to the impairment losses on the amounts due from related parties.

Other Losses — Net

During the six months ended June 30, 2026, we recognised a provision of RMB62.1 million in relation with the Freeze Action disclosed in our announcement dated August 14, 2026 as compared to other losses of RMB0.2 million for the six months ended June 30, 2025.

Finance Income and Expenses

Our finance income decreased from RMB1.7 million for the six months ended June 30, 2025 to RMB0.5 million for the six months ended June 30, 2026, which was mainly a result of the decrease in interest income. Our finance costs for the six months ended June 30, 2026 amounted to RMB4.0 million, mainly consisting of interest expenses related to lease payment.

Income Tax Expense

Our Group incurred an income tax expense of RMB5.9 million for the six months ended June 30, 2026, representing a YoY decrease of 66.7% when compared with our income tax expense of RMB17.7 million for the same period in the previous financial year. Such decrease was mainly due to the loss of our Group.

Loss for the six months ended June 30, 2026

We recorded a loss of RMB101.4 million for the six months ended June 30, 2026 as compared to a loss of RMB58.8 million for the six months ended June 30, 2025.

FINANCIAL POSITION

Inventories

Our inventories decreased by 20.3% from RMB12.8 million as of December 31, 2025 to RMB10.2 million as of June 30, 2026, primarily due to the decrease of requisite medical inventories as a result of the decline of the Group's medical business in the first half of 2026.

Trade Receivables

Our trade receivables decreased by 25.2% from RMB31.0 million as of December 31, 2025 to RMB23.2 million as of June 30, 2026, primarily because of a YoY decrease in medical business.

Trade Payables

Our trade payables decreased by 8.9% from RMB24.6 million as of December 31, 2025 to RMB22.4 million as of June 30, 2026, primarily due to the reduction in the usage of pharmaceuticals and medical consumables and decreased purchases near June 30, 2026.

LIQUIDITY AND CAPITAL RESOURCES

Restricted Cash

As at June 30, 2026, we had restricted cash of RMB217.5 million, which mainly related to an ongoing investigation by the Supervisory Committee involving one of the Company's cooperative partners. Our Group expects the restrictions on the frozen funds to be released within the next twelve months based on current circumstances.

Cash and Cash Equivalents

As of June 30, 2026, we had cash and cash equivalents of RMB61.5 million, which represented a decrease of 73.3% when compared with our cash and cash equivalents of RMB230.3 million as of December 31, 2025.

Significant Investments

Our Group did not hold any significant investments for the six months ended June 30, 2026.

Acquisitions and Disposals

Our Group had no acquisitions or disposals of subsidiaries, associated companies and joint ventures for the six months ended June 30, 2026.

Capital Expenditures

Our capital expenditures primarily include expenditures on

(i) property, plant and equipment which are medical equipment, furniture and office equipment; and

(ii) intangible assets such as computer software relating to our operations.

The amount of our capital expenditures for the six months ended June 30, 2026 was RMB1.3 million, representing a YoY decrease of 75.5% when compared with RMB5.3 million for the same period in the previous financial year.

Such decrease was mainly due to our procurement of certain large-scale property, plant and equipment for business development in 2025, following a decrease in such purchase in the first half of 2026.

INDEBTEDNESS

Borrowings

As of June 30, 2026 and December 31, 2025, we did not have any borrowings.

Exposure to Fluctuations in Exchange Rates

We mainly operate in the PRC with most of the transactions settled in RMB. Foreign exchange rate risk arises when recognized assets and liabilities are denominated in a currency that is not the entity's functional currency. As of June 30, 2026, our assets and liabilities are primarily denominated in RMB, except for certain cash and cash equivalents denominated in USD or HKD and dividends payable denominated in HKD. We have not used any derivative financial instrument to hedge against our exposure to foreign exchange risk but will closely monitor such risk on an ongoing basis.

Contingent Liabilities

As of June 30, 2026, we did not have any contingent liabilities or guarantees that would have a material impact on our financial position or results of operations.

Pledge of Assets

As of June 30, 2026, none of our assets had been pledged.

Contractual Obligations

As of June 30, 2026, we did not have any contractual obligations that would have a material effect on our financial position or results of operations.

Financial Instruments

Our major financial instruments include trade receivables, other receivables and deposits excluding prepayments, amounts due from related parties, restricted cash, cash and cash equivalents, trade payables, other payables excluding non-financial liabilities, amounts due to related parties and lease liabilities. Our management manages such exposure to ensure appropriate measures are implemented in a timely and effective manner.

Gearing Ratio

As of June 30, 2026 and December 31, 2025, we did not have any borrowings, and therefore the gearing ratio, which is calculated as total borrowings divided by total equity, is not applicable.

EMPLOYEE AND REMUNERATION POLICY

We had 1,079 and 1,233 employees as of June 30, 2026 and 2025, respectively. Our total staff remuneration expenses including Directors' remuneration for the six months ended June 30, 2026 and 2025 amounted to RMB140.6 million and RMB161.1 million, respectively. Remuneration is determined with reference to performance, skills, qualifications and experience of the staff concerned and in accordance with the prevailing industry practice. On top of salary payments, other staff benefits include social insurance and housing provident fund contributions made by our Group, performance-based compensation and discretionary bonus. Our Group also adopted the RSA Scheme and the Employee Share Scheme to attract, retain and motivate our key employees.

The remuneration of our Directors is reviewed by the Remuneration Committee and approved by our Board. The relevant Director's experience, duties and responsibilities, time commitment, performance at our Company and the prevailing market conditions are taken into consideration in determining the emolument of our Directors.

INTERIM DIVIDEND

Our Board does not recommend the payment of an interim dividend for the six months ended June 30, 2026.

CORPORATE GOVERNANCE PRACTICE

Our Board is committed to maintaining high corporate governance standards. Our Company has applied the principles as set out in the CG Code contained in Appendix C1 to the Listing Rules which are applicable to our Company.

In the opinion of our Directors, our Company has complied with all applicable code provisions as set out in the CG Code during the six months ended June 30, 2026, save and except for code provision C.2.1 which states that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Jason ZHOU is both our chairman and chief executive officer and is responsible for the overall management of our Group and directing the strategic development and business plans of our Group. We believe that he is instrumental to our growth and business expansion since our establishment in 2002. Our Board considers that the roles of chairman and chief executive officer being vested in the same person is beneficial to the business prospects, management and overall strategic direction of our Group by ensuring consistent leadership within our Group and facilitating more effective and efficient overall strategic planning and decision-making for our Group. After considering all the corporate governance measures that have been taken, our Board considers that the balance of power and authority will not be impaired by the present arrangement and the current structure will enable our Company to make and implement decisions more promptly and effectively. Thus, our Company does not segregate the roles of chairman and chief executive officer. Our Board will continue to review the situation and consider splitting the roles of chairman and chief executive officer of our Company in due course after taking into account the overall circumstances of our Group.

MODEL CODE FOR SECURITIES TRANSACTIONS

Our Company has adopted the Model Code as its code of conduct regarding securities transactions by our Directors. Our Company has also set guidelines, at least as strict as the Model Code, on transactions of our Company's securities for relevant employees (as defined in the Listing Rules).

Our Company has made specific inquiries to all Directors about their compliance with the Model Code, and they all confirmed that they complied with the standards specified in the Model Code during the six months ended June 30, 2026. Our Company has made specific inquiries of relevant employees about their compliance with the guidelines on transactions of our Company's securities, without noticing any violation of the guidelines.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended June 30, 2026, neither our Company nor any of its subsidiaries has purchased, sold or redeemed any of our Company's listed securities.

AUDIT COMMITTEE

Our Audit Committee comprises three independent non-executive Directors, namely, Mr. SUN Hongbin, Mr. JIANG Yanfu and Mr. YANG Yuelin. The chairman of the Audit Committee is Mr. SUN Hongbin.

Our Audit Committee has reviewed the unaudited interim results of our Group for the six months ended June 30, 2026 and was of the opinion that such interim results had been prepared in accordance with the relevant accounting standards and that adequate disclosures have been made in accordance with the requirements of the Listing Rules.

EXTRACT OF REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

The following is an extract of the report on review of interim condensed consolidated financial information for the six months ended 30 June 2026 from the independent auditor of the Company:

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with Hong Kong Accounting Standard 34 "Interim Financial Reporting" as issued by the HKICPA.

Emphasis of matter

We draw attention to Note 10(i) to the interim financial information, which describes the uncertainty regarding the outcome of an ongoing investigation into one of the Group's cooperative partners and the resolution of a matter related to the public-private-partnership arrangement between the Group and the cooperative partner. In connection with the investigation, as at June 30, 2026, certain bank accounts of the Group with a total balance of approximately RMB217,497,000 were frozen, and the Group has recognised a provision of approximately RMB62,125,000 for a probable payment to resolve the matter. Our conclusion is not modified in respect of this matter.

EVENTS AFTER THE REPORTING PERIOD

Except for those disclosed elsewhere in this interim condensed consolidated financial information, there is no significant event of our Group during the period from June 30, 2026 to the date of this announcement.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and our Company (www.ncich.com.cn). The interim report for the six months ended June 30, 2026 containing all the information required by the Listing Rules will be dispatched to the Shareholders (upon request) and made available on the above websites in due course.

DEFINITIONS

"Audit Committee"	the audit committee of the Board;
"Board" or "Board of Directors"	the board of Directors of our Company;
"CG Code"	Corporate Governance Code as set out in Appendix C1 to the Listing Rules;

"China" or "PRC"	the People's Republic of China; for the purpose of this announcement only, references to "China" or the "PRC" do not include Taiwan, the Macau Special Administrative Region of the PRC and Hong Kong;
"Company"	New Century Healthcare Holding Co. Limited (新世紀醫療控股有限公司), a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange;
"Directors"	directors of our Company;
"DRG/DIP Payment"	Diagnosis Related Group (DRG) payment refers to the payment by the diagnosis-related grouping of diseases, where, according to the diagnosis of diseases, treatment modalities and individual characteristics of patients, etc., different diagnosis-related groups are established, each of which a uniform payment standard will be determined for; and Diagnosis-Intervention Packet (DIP) payment refers to the payment by disease point value, which is calculated based on the total annual medical insurance payment, the medical insurance payment ratio and the total point of each medical institution's cases to form the payment standard;
"Employee Share Scheme"	the restricted share award scheme approved and adopted by the Company on August 28, 2020;
"Group", "our Group", "we" or "us"	our Company and its subsidiaries;
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC;
"HKICPA"	Hong Kong Institute of Certified Public Accountants;
"HKFRS"	Hong Kong Financial Reporting Standards;
"HK$" or "HKD"	Hong Kong dollars, the lawful currency of Hong Kong;
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended and supplemented from time to time;
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules;

"Remuneration Committee"	the remuneration committee of our Board;
"RMB"	Renminbi, the lawful currency of the PRC;
"RSA Scheme"	the restricted share award scheme approved and adopted by the Company on August 29, 2016;
"Share(s)"	ordinary share(s) of US$0.0001 each in the issued capital of our Company or if there has been a subsequent sub-division, consolidation, reclassification or reconstruction of the share capital of our Company, shares forming part of the ordinary equity share capital of our Company;
"Shareholder(s)"	holder(s) of the Share(s);
"Stock Exchange"	The Stock Exchange of Hong Kong Limited;
"Supervisory Committee"	Beijing Mentougou Supervisory Committee (北京市門頭溝區監察委員會);
"US$" or "USD"	United States dollars, the lawful currency of the United States;
"YoY"	year-on-year; and
"%"	percent.

In this announcement, the terms "connected person", "controlling shareholder" and "subsidiary" shall have the meanings given to such terms in the Listing Rules, unless the context otherwise requires.

By Order of the Board
New Century Healthcare Holding Co. Limited
Mr. Jason ZHOU
Chairman, Executive Director and Chief Executive Officer

Hong Kong, August 31, 2026

As of the date of this announcement, the Board comprises Mr. Jason ZHOU, Ms. XIN Hong and Mr. XU Han, as executive Directors; Ms. LI Suyu, Mr. XIE Qiang, Mr. ZHAO Qin and Mr. QIU Xiang, as non-executive Directors; and Mr. WU Guanxiong, Mr. SUN Hongbin, Mr. JIANG Yanfu, Dr. MA Jing and Mr. YANG Yuelin, as independent non-executive Directors.